|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS Mutation Predicted More Mirometastases and Closer Resection Margins in Patients with Colorectal Cancer Liver Metastases.
|
31720935 |
2020 |
|
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Left-sided tumors with wild-type KRAS had greater proportion of liver metastasis (78.6% versus 53.5%, P = 0.00), whereas those with mutant KRAS had greater proportion of lung metastasis (23.3% versus 8.7%, P = 0.02).
|
30737098 |
2020 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the six locally advanced cases, KRAS mutation appeared concurrently with liver metastasis.
|
31746520 |
2020 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Does KRAS mutation status impact the risk of local recurrence after R1 vascular resection for colorectal liver metastasis? An observational cohort study.
|
31839435 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update.
|
31426677 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Univariate (p = .011) and multivariate analyses (p = .005) showed that KRAS genotype in liver metastases was predictive of LTP.
|
30663903 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
m-KRAS is associated with worse OS in patients presenting with colorectal cancer and liver metastases undergoing resection of the primary tumor and metastatic disease.
|
30276588 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases.
|
30979646 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with resected CRLM treated at MSKCC with and without adjuvant HAI who had available KRAS status (wild-type, WT; mutated, MUT) were reviewed from a prospectively maintained institutional database.
|
30817353 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Further workup revealed that circulating tumor-derived DNA and liver metastases originated from a synchronous KRAS-mutated cancer of the pancreas.
|
31134762 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
On WES analysis, primary carcinoma with desmoplastic liver metastasis showed mutations in APC (4/5); TP53 (3/5); KRAS, PIK3CA, and FAT4 (2/5); BRCA-1, BRCA2, BRAF, and DNAH5 (1/5), whereas primary carcinoma with replacement liver metastasis showed mutations in APC and TP53 (3/5); KRAS, FAT4, DNH5, SMAD, ERBB2, ERBB3, LRP1, and SDK1 (1/5).
|
31341365 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively evaluated 155 patients with KRAS exon 2 wild-type CLM treated with bevacizumab (BEV group) or anti-EGFR antibodies (EGFR group).
|
30396978 |
2018 |
|
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
From a translational perspective, the identification of this KRAS-driven pathway might provide a mechanistic rationale for the use of a MEK inhibitor as an adjuvant, in combination with standard of care, to prevent the recurrence of colorectal liver metastasis in KRAS mutant CRC patients after receiving liver resection, which warrants further investigation.
|
29559746 |
2018 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C).
|
29409955 |
2018 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?
|
29580164 |
2018 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, modified mismatch PCR-RFLP protocol is a suitable method in this setting to detect K-ras gene mutations predicting liver metastasis in CRC patients.
|
28169239 |
2017 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases.
|
28657938 |
2017 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies.
|
28004119 |
2017 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS Mutation Status Dictates Optimal Surgical Margin Width in Patients Undergoing Resection of Colorectal Liver Metastases.
|
27696170 |
2017 |
|
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cetuximab combined with systematic chemotherapy perhaps suggests a promising choice for KRAS wild type patients with unresectable liver metastases.
|
28167959 |
2017 |
|
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lung metastasis was more frequently involved in patients with KRAS mutation (50.0% vs. 22.6%, p = 0.006), and liver metastasis was more frequently involved in patients with WT KRAS (81.1% vs. 55.0%, p = 0.007).
|
28161825 |
2017 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate Cox regression analysis revealed poor preoperative chemotherapy response, Fong clinical risk score > 2, and KRAS mutation to be independent prognostic indicators in CRLM patients.
|
29108374 |
2017 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tumor regression grades, K-RAS mutational profile and c-MET in colorectal liver metastases.
|
28559118 |
2017 |
|
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to the discordant results (GGT->GTT exon 2 KRAS mutation in the primary tumor, and KRAS-WT in the liver metastases), mutational analysis on liver metastasis was repeated using next-generation sequencing and enriching the sample in tumor cells by manual microdissection; the same type of mutation of the primary tumor (GGT->GTT exon 2 KRAS gene) was confirmed.
|
28665451 |
2017 |
|
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, when <i>de novo</i> mutations were defined as a total count of zero in F0 and ≥5 in F2, exactly prognostic impact of clone cancer profiling (EGFR, KRAS, BRAF, PIK3CA, NRAS, APC and TP53) were detected in the paired.
|
29094026 |
2017 |